STOCKHOLDERS' EQUITY	6 Months Ended
Feb. 28, 2019
Notes to Financial Statements
Note 7. STOCKHOLDERS' EQUITY	In August 2012, the Company authorized the issue of 100,000,000 common shares of the Company at par value of $.0001 and authorized the issue of 10,000,000 preferred shares at par value of $.0001. On October 26, 2018 the Company completed a 1,000 to 1 reverse stock split of the common shares. The stock split has been recorded in these financial statements retroactively. At February 28, 2019, there are total of 32,517 common shares of the Company issued and outstanding.

STOCKHOLDERS' EQUITY

6 Months Ended

Feb. 28, 2019

In August 2012, the Company authorized the issue of 100,000,000 common shares of the Company at par value of $.0001 and authorized the issue of 10,000,000 preferred shares at par value of $.0001.

On October 26, 2018 the Company completed a 1,000 to 1 reverse stock split of the common shares. The stock split has been recorded in these financial statements retroactively.

At February 28, 2019, there are total of 32,517 common shares of the Company issued and outstanding.

Blake Insomnia Therapeutics, Inc. 10-Q